Status:
COMPLETED
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Pediatric Cancer
Febrile Neutropenia
Eligibility:
All Genders
1-17 years
Brief Summary
In this pilot study the feasibility continous recording of vital signs in pediatric patients under chemotherapy for cancer, is studied. Vital signs and are recorded with two different wearable device...
Detailed Description
In a previous study (Bern 2019 WD Pilot, NcT04134429) the investigators found that continuous recording of vital signs with the Everion® is feasible in good quality across a wide age range (3 to 16 ye...
Eligibility Criteria
Inclusion
- Chemotherapy treatment because of any malignancy, expected to last ≥1 month at time of recruitment for myelosuppressive therapy; or at least one cycle of myeloablative therapy requiring autologous (Bern/Basel) or allogeneic (Basel) hematopoietic stem cell transplantation.
- Age from 1 month to 17.99 years at time of recruitment
- Written informed consent from parents and participants, where applicable
Exclusion
- Local skin diseases prohibiting wearing of the WD.
- Denied written informed consent from participants
Key Trial Info
Start Date :
September 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04914702
Start Date
September 16 2021
End Date
March 1 2022
Last Update
July 11 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Children's Hospital Basel, University of Basel
Basel, Switzerland
2
Inselspital
Bern, Switzerland, 3010